The future of drug discovery and development lies in 3D human tissue models. The latest generation of 3D in vitro models are highly predictive, stable over long periods of time (thus appropriate for assessing complex treatment regimens), and permit the cultivation of organotypic tissues, composed of all the relevant cell types required to recapitulate human in vivo physiology. They allow to recapitulate complex diseases such as NAFLD/NASH/fibrosis in the liver field, Type 1 and Type 2 diabetes in pancreatic research or the heterogeneity in oncology using PDX models. Fully exploiting complex biology requires precisely engineered culturing platform not only supporting tissue function, but building a seamless interface to operation and analysis. In this tutorial, we will present our scalable 3D microtissue models together with our specifically engineered, ANSI/SLAS-compatible plates such as 96-well, 384-well and organ-on-a-chip formats. All are highly compatible with state-of-the-art imaging and automation equipment as well as most assay endpoints. Our unique technology platform enables researchers to complement and reduce reliance on animal experiments, saving significant time and resources in the drug development process and giving ensuring higher confidence in decision making for later clinical stages.
In the tutorial, we will focus on the reliability of handling of 3D microtissues in robust assay setups and how to achieve model and parameter continuity across different plate technologies.